The experimental results showed that CPT-TMC could significantly reduce tumor-related blood vessel and lymphangiogenesis, participate in the down-regulation of VEGF-D and MMP-9 expression, increase tumor apoptosis index, maximize the anti-tumor and anti-metastasis activity of CPT, and reduce systemic side effects caused by drugs. The gene discussed is MMP9; the disease is neoplasm.